Evox Therapeutics Ltd, a leading exosome therapeutics company, today announces that it has secured an undisclosed amount of funding from the Bill & Melinda Gates Foundation. The funds will be used to support the Company’s development of cell-targeted exosome-based approaches to more effectively deliver a nucleic acid-based anti-infective drug.
Evox Therapeutics is engineering exosomes, the body’s natural vesicular delivery system, to enable a wide variety of drugs to reach previously inaccessible tissues and compartments, such as crossing the blood-brain barrier to deliver drugs to the central nervous system, intracellular delivery of biologics, and extra-hepatic delivery of RNA therapeutics.
Dr. Antonin de Fougerolles, Chief Executive Officer of Evox, commented: “We are pleased to be working with the Bill & Melinda Gates Foundation to maximize the effectiveness of their therapeutic drug through cell- and tissue-targeted exosome-mediated delivery. The foundation has a reputation for working with partners that can drive meaningful change – this funding is a testament to the quality of our platform and its potential application in areas of high medical need.”